Bayer Shifting Further To Emerging Markets Including China
This article was originally published in PharmAsia News
Executive Summary
Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets
You may also be interested in...
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
SHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai